Clinical trial
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously…
NCT00269828 · CTI BioPharma, Industry · Terminated
Key facts
| NCT number | NCT00269828 |
|---|---|
| Title | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. |
| Official title | Paclitaxel Poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Women With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Who Are Performance Status 2. |
| Acronym | PIONEER |
| Lead sponsor | CTI BioPharma, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | NSCLC |
| Intervention type | Drug |
| Interventions | paclitaxel, paclitaxel poliglumex |
| Enrollment | 600 |
| Start date | Dec 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Dec 26, 2005 |
| Last update posted | Nov 24, 2020 |
| Countries | Argentina, Bulgaria, Canada, Hungary, Mexico, Poland, Romania, Russia, Ukraine, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: